Search research articles
Contact Us
Filters
Showing results (101-110 of 115) with videos related to
Page
of 12
Sort By:
Journal for Immunotherapy of Cancer
|
October 6, 2025
Preliminary qualification of a machine learning-based assessment of the tumor immune infiltrate as a predictor of outcome in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab
Bernhard Scheiner, Pasquale Lombardi, Antonio D'Alessio, et al.
JHEP Reports : Innovation in Hepatology
|
January 29, 2025
Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab/bevacizumab
Meng Wu, Claudia A M Fulgenzi, Antonio D'Alessio, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
May 26, 2026
Predicting decompensation in unresectable hepatocellular carcinoma on atezolizumab plus bevacizumab: the ARTE Score
Lorenzo Canova, Eleonora Alimenti, Lorenzo Argiento, et al.
Journal of Hepatocellular Carcinoma
|
April 9, 2025
ALBI Grade Enables Risk Stratification for Bleeding Events and Refines Prognostic Prediction in Advanced HCC Following Atezolizumab and Bevacizumab
Bernardo Stefanini, Claudia Angela Maria Fulgenzi, Bernhard Scheiner, et al.
JHEP Reports : Innovation in Hepatology
|
February 12, 2026
Reproducible safety and efficacy of durvalumab with or without tremelimumab for hepatocellular carcinoma in clinical practice: Results of the DT-real study
Ciro Celsa, Tiziana Pressiani, Naoshi Nishida, et al.
Gut
|
March 20, 2021
Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis
Victor Sapena, Marco Enea, Ferran Torres, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
December 14, 2024
Noninvasive Assessment of portal Hypertension in Patients With Primary Biliary Cholangitis is Affected by Severity of Cholestasis
Vincenza Calvaruso, Ciro Celsa, Laura Cristoferi, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 24, 2026
Determinants of long-term survival from atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Pei-Chang Lee, Alessio Cortellini, Bernardo Stefanini, et al.
Hepatology (Baltimore, Md.)
|
July 19, 2024
Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment
Ciro Celsa, Giuseppe Cabibbo, Claudia Angela Maria Fulgenzi, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
June 19, 2026
Mortality Attributable to Hepatitis B and C in Italy, Romania, and Spain, 2022 Estimates
Oleksandr Korotych, Helene Høgsbro Thygesen, Otilia Mårdh, et al.
Page
of 12
Search research articles
Search
Showing results (101-110 of 115) with videos related to
Sort By:
Page
of 12
Journal for Immunotherapy of Cancer
|
October 6, 2025
Preliminary qualification of a machine learning-based assessment of the tumor immune infiltrate as a predictor of outcome in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab
Bernhard Scheiner, Pasquale Lombardi, Antonio D'Alessio, et al.
JHEP Reports : Innovation in Hepatology
|
January 29, 2025
Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab/bevacizumab
Meng Wu, Claudia A M Fulgenzi, Antonio D'Alessio, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
May 26, 2026
Predicting decompensation in unresectable hepatocellular carcinoma on atezolizumab plus bevacizumab: the ARTE Score
Lorenzo Canova, Eleonora Alimenti, Lorenzo Argiento, et al.
Journal of Hepatocellular Carcinoma
|
April 9, 2025
ALBI Grade Enables Risk Stratification for Bleeding Events and Refines Prognostic Prediction in Advanced HCC Following Atezolizumab and Bevacizumab
Bernardo Stefanini, Claudia Angela Maria Fulgenzi, Bernhard Scheiner, et al.
JHEP Reports : Innovation in Hepatology
|
February 12, 2026
Reproducible safety and efficacy of durvalumab with or without tremelimumab for hepatocellular carcinoma in clinical practice: Results of the DT-real study
Ciro Celsa, Tiziana Pressiani, Naoshi Nishida, et al.
Gut
|
March 20, 2021
Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis
Victor Sapena, Marco Enea, Ferran Torres, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
December 14, 2024
Noninvasive Assessment of portal Hypertension in Patients With Primary Biliary Cholangitis is Affected by Severity of Cholestasis
Vincenza Calvaruso, Ciro Celsa, Laura Cristoferi, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 24, 2026
Determinants of long-term survival from atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Pei-Chang Lee, Alessio Cortellini, Bernardo Stefanini, et al.
Hepatology (Baltimore, Md.)
|
July 19, 2024
Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment
Ciro Celsa, Giuseppe Cabibbo, Claudia Angela Maria Fulgenzi, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
June 19, 2026
Mortality Attributable to Hepatitis B and C in Italy, Romania, and Spain, 2022 Estimates
Oleksandr Korotych, Helene Høgsbro Thygesen, Otilia Mårdh, et al.
Page
of 12